Uncategorized

While XEN1101 failed to hit the primary endpoint in a Phase II trial, the Canadian company is “actively exploring” further development of the program based on the totality of the data.

Johnson & Johnson, Medtronic and Abbott were among the top companies to announce layoffs this year as the industry implemented cost-cutting measures.

Pegozafermin showed statistically significant improvements in treating patients with nonalcoholic steatohepatitis, notching a win in the race to get the first treatment to market for the condition.

The agency has become “concerned with the divergent harmonization efforts for medical devices” and will focus on working with the International Medical Device Regulators Forum going forward.

The nonprofit remained in the black for the first nine months of 2023, but performance dipped slightly in the third quarter.

Bioventus’ protracted buyout bid ultimately fell apart and opened the door to Smith & Nephew.

Researchers reviewed almost 300 pieces of literature on 340B and found some studies that suggested hospitals were using savings from the program for purposes “seemingly unrelated” to patient care.

The medical device maker warned that the incident is expected to continue to disrupt its business operations.

New data show the chronic obstructive pulmonary disease candidate significantly reduced exacerbations, confirming positive results from an earlier trial.

A year after exiting the U.S. market, GSK is setting the stage for the antibody-drug conjugate’s possible return in relapsed/refractory multiple myeloma.